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2Abstract
The amyloid precursor protein (APP), that plays a critical role in the development of senile 
plaques in Alzheimer disease (AD), and the gp41 envelope protein of the human 
immunodeficiency virus (HIV), the causative agent of the acquired immunodeficiency 
syndrome (AIDS), are single-spanning type-1 transmembrane (TM) glycoproteins with the 
ability to form homo-oligomers. In this review we describe similarities, both in structural 
terms and sequence determinants of their TM and juxtamembrane regions. The TM 
domains are essential not only for anchoring the proteins in membranes but also have
functional roles. Both TM segments contain GxxxG motifs that drive TM associations 
within the lipid bilayer. They also each possess similar sequence motifs, positioned at the 
membrane interface preceding their TM domains. These domains are known as cholesterol 
recognition/interaction amino acid consensus (CRAC) motif in gp41 and CRAC-like motif 
in APP.  Moreover, in the cytoplasmic domain of both proteins other a-helical 
membranotropic regions with functional implications have been identified. Recent drug 
developments targeting both diseases are reviewed and the potential use of TM interactions 
modulators as therapeutic targets is discussed.
Key words: gp41, amyloid precursor protein, transmembrane segment, membrane, HIV, 
Alzheimer.
3Introduction
Biological membranes are complex mixtures composed primarily of lipids and proteins. 
Although membrane proteins represent approximately one third of all proteins encoded in 
the human genome, and are involved in almost every aspect of cell biology and physiology, 
there is still little knowledge about how these proteins act and interact in biological 
membranes [1]. This is despite more than half of currently marketed pharmaceuticals 
targeting membrane proteins [2].
The vast majority of membrane proteins are anchored to cellular membranes through 
transmembrane (TM) domains that predominantly adopt an a-helical secondary structure
[3].  Membrane-spanning a-helices, rather than serving merely as featureless hydrophobic 
stretches required for anchorage and facilitating insertion of proteins in membranes, have 
recognized functions well beyond these classical roles (for recent overviews see [4, 5]).  
The organization and number of TM segments varies between membrane proteins, but it is 
generally believed that van der Waals interactions play an important role in the packing of 
TM domains. These interactions compensate for the lack of the hydrophobic effect that 
drives the folding of water-soluble proteins. Modulation of TM helix-helix interactions 
provides new exciting means to regulate the functions of membrane proteins. It is well 
established that homo- or heterodimerisation, trimerisation and other types of TM 
associations play important roles in different biological processes [5].  In the present 
review, we will discuss recent results on the structure, packing determinants and assembly 
of the TM domains of HIV gp41 and APP. These are both membrane proteins implicated in 
human diseases of paramount importance.  The development of exogenous agents that 
4recognize TM domains can be used for rational drug design [1, 6], and by interfering with 
TM interactions new targeted therapeutics should be expected in the near future.
HIV Envelope (Env) Glycoproteins
Human immunodeficiency virus type-1 (HIV-1) is an enveloped virus that gains entry into 
target cells by mediating the fusion of viral and cellular membranes.  Entry into cells is 
directed by the envelope (Env) glycoproteins, which are present on the surface of HIV-1 
virions as trimers [7]. HIV-1 Env complex is synthesized as a type-1 TM gp160 precursor, 
which undergoes oligomerization, disulfide bond formation and extensive glycosylation, 
and is then post-translationally cleaved into the surface receptor binding subunit gp120 and 
the TM fusion protein gp41 [8], which remain non-covalently associated [9].
The full-length monomeric gp41 TM glycoprotein consists of three domains (Figure 
1A): an ectodomain (ECD), a TM domain and a large cytoplasmic domain (CTD).  Several 
regions in the ECD are important for membrane fusion activity (see refs [10, 11] for recent 
reviews).  A highly conserved (glycine-rich) hydrophobic fusion peptide (FP), located at 
the extreme N-terminus; N- and C-terminal heptad repeat (HR) regions (NHR and CHR), 
connected by a glycosylated 30-40 residues disulfide-bonded loop; and a tryptophan-rich 
membrane proximal ectodomain region (MPER).  Binding of gp120 to the CD4 cellular 
receptor on the surface of target cells triggers a series of conformational changes in gp120 
subunit that facilitate gp120 binding to a co-receptor, CXCR4 or CCR5, and the exposure 
of the hydrophobic gp41 fusion peptide. The dynamics of gp41 conformational changes 
triggering membrane fusion have been reviewed extensively [11-13]. Briefly, three gp41 
NHR regions can adopt a parallel triple-stranded coiled-coil configuration that enables 
penetration of the gp41 fusion peptide into the membrane of the target cell. Subsequent 
5refolding of gp41 heptad repeat (HR) regions into a six-helix bundle structure (trimer of 
hairpins) forces the juxtaposition of the viral and cell membranes, promoting their fusion 
[14]. Recently, it has been demonstrated the C-terminal boundary of this six-helix bundle 
fusion conformation in an ongoing dynamic fusion process [15]. At present, it is thought 
that the structural rearrangements in the gp41 TM glycoprotein are crucial for the 
membrane fusion process and viral entry [16].
gp41 Membranotropic Sequences
Although gp41 six-helix bundle formation is the main driving force for the fusion process, 
other gp41 regions in the ECD may regulate fusion activity in numerous ways.  The role of 
the N-terminal fusion peptide region and its implication in membrane destabilization and 
fusogenic activity has been analyzed in recent reviews [10, 11].  The membrane 
conformation of the fusion peptide (a-helical/b-strand/disordered) deduced from 
chemically synthesized FPs in model membranes is controversial [17-19], probably due to 
an effect of microenvironment composition dictating the adopted conformation [20]. In this 
context, gp41 FP, which is unstructured in solution, adopts an a-helical structure in 
micelles [21, 22], inserting its N-terminal residues in an a-helical conformation and 
presenting a flexible hinge reminiscent of the kinked structure proposed for several N-
terminal fusion peptides [23-26]. Structural plasticity of gp41 FP has been also observed 
depending on peptide concentration. When bound to lipid bilayers at low concentration 
gp41 FP is largely a-helical, however, at higher protein/lipid ratios the domain is partially 
converted to form b-structures [19]. A 13C FTIR study have demonstrated that this peptide 
adopts intermolecular parallel b-sheet structure in membranes when stabilised by the 
6adjacent N-terminal heptad repeat [27]. Recent 2D correlation spectra and distance 
measurements from solid-state NMR-spectroscopy in cholesterol-containing host-cell-like 
membranes indicated that the fusion region had predominantly a b-strand conformation 
[28], with 50-60% population of antiparallel strand orientation [29], that allows close 
proximity of the A525-G527 region with the lipid headgroups, which would likely perturb 
the cell membrane [30]. Perhaps both a-helical and b-sheet structures are relevant at 
different stages of HIV fusion process. Given its a-helix to b-sheet interconversion, 
elevated alanine and glycine levels, fusogenicity and plaque formation, gp41 FP has been 
proposed as an ‘amyloid homolog’ (or ‘amylog’) [31, 32], and more recent results suggest 
that bound to membranes, FP may contribute to cytopathicity of HIV through amyloid-type 
mechanism [33].
The gp41 ECD region preceding the TM domain is designated as MPER (membrane-
proximal ECD region), or pre-transmembrane, preTM region (reviewed in [34]). This 
region, which is predicted to form an a-helical conformation on membrane contact (Figure 
2A), contains highly conserved hydrophobic residues and is unusually rich in tryptophan 
residues (see Figure 1A). The basis for the invariant nature of the tryptophans appears to be 
at the level of glycoprotein incorporation into virions, since mutants in this region reduce 
glycoprotein incorporation and drop the efficiency of virus entry while had no significant 
effect on syncytium formation [35].  The MPER region actively participates in the 
clustering of gp41 within the HIV-1 envelope, and in destabilization of the bilayer 
architecture at the loci of fusion. Interestingly, the MPER carboxy-terminus has a LWYIK 
sequence immediately preceding the TM segment (see Figure 1A) that can be identified as 
a ‘cholesterol recognition/interaction amino acid consensus’ (CRAC) motif [36-39].  A 
7number of studies have shown that cholesterol-enriched microdomains (lipid rafts) play 
important roles in both early and late phases of the HIV lifecycle (reviewed in [40, 41]). 
MPER-Cholesterol complex might form at the interface of the external viral membrane 
monolayer, with the potential of inducing membrane perturbations upon self-assembly [35, 
42].  Monolayer intrinsic curvatures could hypothetically change their sign from positive to 
negative curvature upon MPER desorption, thus facilitating fusion pore opening [34].  
Recent mutational studies suggest that both structural (for gp41 stability and incorporation) 
and functional (membrane disruption) constraints may contribute to the highly conserved 
nature of the membrane-proximal ECD region [43]. More recently, it has been shown that 
the highly conserved LWYIK motif acts as a structural determinant in modulating 
membrane fusion and post-fusion events [44], and that intact plasma membrane cholesterol 
and lipid raft microdomains are essential for HIV entry in macrophages, a critical target cell 
type for HIV-1 [45].
The MPER may act in conjunction with other regions in the gp41 ECD to maintain 
the native and fusion states. The FP and MPER sequences can assemble restricting FP-
mediated fusion [46, 47]. Extensive studies with synthetic peptides have recently pointed 
out that the MPER W666-N677 segment interacts with a fusion peptide proximal region 
S528-Q540 (FP-PR, Figure 1A), and that this interaction contributes to stabilize gp41 six-
helix bundle formation [48]. FP-PR and MPER can act synergistically in forming a fusion-
competent gp120/gp41 complex and in stabilizing the membrane-interactive end of the 
trimer of hairpins [49]. In fact, hydrophobicity-at-interface analysis of gp41 MPER mutants 
[34] predicts the existence of a gp41 region anchored to the viral membrane through an 
interfacial sequence, amphipathic at its N-terminus, which is followed by the hydrophobic 
TM domain (Figure 2A).
8Other membranotropic regions have been located in the gp41 cytoplasmic domain 
(Figure 2A). Thus, the lentiviral lytic peptide (LLP) sequences [50-52], three amphipatic 
helical segments, might function in modulating fusogenicity during envelope processing 
and viral membrane fusion or budding [11, 53].  Also, progressive truncations and point 
mutations in the gp41 cytoplasmic tail have demonstrated that the C-terminal end plays a 
key role in coupling HIV-1 fusion competence to virion maturation [54]. Furthermore, 
photoinduced chemical reaction studies with a membrane embedded probe provide a 
further demonstration that portions of gp41 cytoplasmic tail are partially inserted into the 
viral membrane [55].
gp41 Transmembrane Domain
The gp41 TM domain is one of the most conserved regions of the gp41 sequence among 
independent isolates of HIV-1, and is primarily responsible for anchoring the envelope 
glycoproteins into the viral membrane (Figure 2A). In contrast to the membrane-spanning 
region of most viral envelope proteins that consist of stretches of hydrophobic amino acids, 
the TM region of lentivirus envelope glycoproteins is generally interrupted by charged 
residues [56].  In this regard, HIV-1 not only has one lysine (K683) and two arginines 
(residues 707 and 709) flanking the membrane-spanning region, but also contains one basic 
residue (R696) that is predicted to be located within the hydrophobic TM region (Figure 
1A). In the absence of high-resolution structural information on the HIV-1 TM domain, the 
exact length of this region remains unresolved. At present, two models have been proposed 
for the membrane spanning of HIV-1 gp41 protein. In the first model 25 amino acid 
residues were suggested to cross the membrane as an a-helix, with a length similar to the 
thickness of the lipid bilayer [57].  In this model R696 is placed in the hydrophobic core of 
9the bilayer, without any known mechanism to neutralize the basic groups. In this context, 
C-terminal truncation studies of simian immunodeficiency virus (SIV) [58] and HIV-1 [59]
indicate that the entire 25-amino acid region is not required for the biological function of 
Env glycoproteins. Therefore, a second model was proposed [58] based on the capacity of 
polar residues to ‘snorkel’, i.e. they may bury their aliphatic part in the hydrophobic region 
of the lipid bilayer, while positioning the charged group in the more polar interface. In this 
model, twelve amino acid residues will form the hydrophobic helical core buried within the 
membrane [59], with K683 and R696 (BH10 isolate numbering) residues flanking the 
hydrophobic core region. Thus, membrane-embedded charged residues can be neutralized 
by side-chain interactions with negatively charged lipid polar head groups. This latter 
membrane disposition precludes any polar residues from being placed at the hydrophobic 
lipid core since the polypeptide membrane-spanning region is significantly reduced, 
probably accompanied by elastic distortion of the surrounding lipid chains [60]. 
Interestingly, influenza virus hemagglutinin (HA) studies have indicated similar TM 
requirements. The presence of a single arginine residue allowed a shortened HA TM 
domain to span the bilayer, most likely by an interaction between the guanidinium group 
with phosphate head groups of the viral membrane [61].
The process of membrane fusion initiated by gp120-CD4 binding seems to be 
dependent on the structural integrity of the TM domain [62], and it was found that a 
minimum length of the TM segment was crucial for the membrane fusion function of the 
protein [63]. Thus, in addition to membrane anchorage, gp41 TM domain may be directly 
or indirectly involved in membrane fusion events. In fact, the replacement of the HIV-1 
TM segment with a glycophospholipid anchor abrogated both cell-cell fusion and virus-cell 
fusion, though the chimeric protein could be normally expressed, processed, and 
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incorporated into virions [64]. Also, the complete substitution of gp41 TM segment by that 
of cellular glycophorin A (GpA), vesicular stomatitis virus G protein (VSV-G), or HA
glycoprotein was found to severely impair the fusion activity of the chimeric molecules 
[65, 66]. 
According to the consensus sequence of HIV-1 TM segment [59], the twelve amino 
acid residues in the core region (L684-L695, Figure 1A) are more conserved than those in 
the flanking residues. Within these hydrophobic residues, recent studies have focused on 
the GxxxG motif (G, glycine; x, other amino acid residues), since these glycine residues are 
the most conserved among all HIV-1 TM sequences [59, 65, 67]. This motif is often 
observed in TM a-helices of both cellular and viral proteins (Figure 3), and has been 
proven to stabilize helix-helix interactions of membrane proteins [3].  In the case of GpA, 
this motif is critical for homodimerisation [68, 69], although surrounding residues might 
‘fine-tune’ the affinity of helix-helix interaction [70-72]. In fact, the length of the 
hydrophobic region has also been found to be critical for in vitro dimerisation of the native 
GpA sequence [73], as well as in a polyleucine scaffold where the dimerisation motif was 
grafted [74]. Similarly, the GxxxG motif in the E1 glycoprotein of hepatitis C virus 
(HCVE1) is important for the heterodimerisation of its E1 and E2 envelope glycoproteins 
[75]. On the other hand, structural and functional studies of a gp41 construct comprising 
the complete C-terminal heptad repeat region, the connecting region, and the TM segment 
have shown that the TM domain of gp41 is sufficient to drive trimerisation in vitro [57].
While the TM domain of HIV-1 gp41 is highly resistant to amino acid exchanges, 
mutations in the GxxxG motif (G690-G694) affected viral fusion events [65-67].  In 
particular, HIV-1 gp41 TM segment has a glycine residue at position 691 that forms a 
GGxxG sequence. Replacement of G691 with alanine, phenylalanine or leucine, decreased 
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the efficiency of membrane fusion, with the major effect occurring with the leucine 
substitution [67].  Substitution with leucine residue also decreased the incorporation of 
gp41 protein into virions, suggesting that the steric nature of the side chain of the residue at 
position 691 is important for gp41 function.  In the light of these results, a model for the 
association among three TM helices of gp41 has been proposed in which the GxxxG motif 
is facing inward of the trimeric structure and G691 locates itself near the helix-helix 
interface [67]. This model places the highly conserved arginine residue (R696) toward the 
lipid environment, which is in principle a thermodynamically unfavourable arrangement. 
However, arginine residues may be accommodated into a lipid bilayer more easily than 
expected [76-78]. In any case, since the atomic structure of the gp41 TM segment in lipid 
environment has not been yet solved, other putative arrangements of the trimeric gp41 TMs 
are also possible.
Recently, the hydrophobic core region of gp41 TM segment was replaced with 12 
leucine residues (L12 mutant) and recovery-of-function mutants then constructed in which 
specific amino acid residues (including a GGxxG motif) were reintroduced [59].  Mutant 
L12 was defective in mediating virus infectivity and cell-cell fusion. The GGxxG motif 
was found critical for the membrane fusion process mediated by gp41, since reintroduction 
of this motif into the leucine scaffold of the L12 mutant significantly increased the 
efficiency of cell-cell fusion and infectivity of HIV-1.  Moreover, improvement of gp41 
fusogenicity was achieved by reintroducing additional F685 and V689 (BH10 isolate 
numbering). Thus, several of the 12 amino acid residues in the HIV-1 TM core region were 
implicated in the efficiency of gp41-mediated membrane fusion, consistent with the high 
conservation of this sequence. Probably, gp41 GGxxG motif can facilitate TM-TM 
interactions that are necessary for the formation of higher-order fusion pore [59].  
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Membrane fusion reactions catalyzed by viral fusion proteins require the concerted action 
of multiple fusion protein trimers [79], and for some HIV-1 isolates between 7 and 14 
trimers have been suggested [80]. Lipid mixing precedes Env recruitment [81], and it has 
been proposed that the merge of the outer leaflets of apposing membranes could initiate 
with one or few functional trimers at the contact site, with further progress facilitated by the 
continuous recruitment of adjacent Env subunits [81].
A wealth of information indicates then that HIV fusion proteins mediate membrane 
fusion by forming a trimeric conformer. It is tempting to speculate that helix-helix 
interactions between the gp41 TM segments might be initially responsible for the induction 
of trimer formation, previous to the trimer-of-hairpins folding that is triggered by the 
heptad repeat regions. As a matter of fact, a chimeric version comprising the gp41 TM 
domain but lacking the full heptad repeat regions showed that the TM segment constitutes 
the trimerisation domain [57]. Hence, interfering gp41 TM interactions may become an 
interesting target in AIDS research including development of new and novel anti-HIV 
inhibitors.
HIV-1 Env-Mediated Membrane Fusion (Entry) Inhibitors
HIV enters its target cells by means of a sequence of molecular events that provides one of 
most attractive targets for inhibitor development. Recent reviews have analyzed CD4-
inhibitors and co-receptor-binding inhibitors [4, 10, 11, 82, 83]. On the other hand, receptor 
recruitment, a prerequisite for fusion, has been shown to be sensitive to lipid modulation, 
and a number of strategies have been used to alter lipid content of target cells in order to 
decrease their susceptibility to HIV-1 entry (reviewed in [11]). Other peptide-based 
inhibitors derived from gp41 NHR and CHR regions such as T21, N36, T20, C34 (Figure 
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1A) and chimeric proteins, or small-molecule inhibitors, that interfere with intermediate 
gp41 structural arrangements have been extensively studied and reviewed elsewhere [10, 
83-86]. 
Despite all these entry inhibitor developments, at present UK-427857 (Maraviroc, 
Selzentry (Pfizer)), an attachment inhibitor that blocks the chemokine receptor CCR5, and 
T20 (Enfuvirtide, Fuzeon (Roche)) are the only FDA-approved HIV inhibitors used for 
AIDS treatment in patients that fail to respond to antiretroviral therapeutics, but can easily 
induce drug resistance. Relative to Maraviroc, researchers also question the long-term 
safety of blocking CCR5, a receptor whose function in healthy individuals is currently not 
fully understood. In last years, efforts directed to enhance the biological potency of peptide-
based inhibitors, i.e., a-helix-inducible X-EE-XX-KK motifs have been applied to design a 
CHR-based enfuvirtide analogue that exhibits highly potent anti-HIV activity in vitro [87]. 
Novel peptide fusion inhibitors have also been designed based on the gp41 fusogenic-core 
structure involving the upstream region of the binding domain in the CHR region. These 
peptides have been found highly effectives against HIV-1 variants resistant to T20 and C34 
[88, 89]. Another anti-HIV peptide, termed sifuvirtide, which is based on the three-
dimensional structure of the gp41 fusogenic core, exhibits high potency against infections 
by a wide range of primary and laboratory-adapted HIV-1 isolates and T20-resistant strains, 
and is currently in Phase II of clinical studies [90]. Finally, concerning gp41 
membranotropic regions, using a synthetic combinatorial library several hexapeptides were 
identified that inhibited fusion peptide activity in model membranes [91].
Amyloid precursor protein and Alzheimer disease
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Alzheimer disease (AD) is characterized by the presence of two types of lesions in the 
brain: neurofibrillary tangles and senile plaques. Amyloid precursor protein (APP) is a 
ubiquitous-glycosylated type-1 TM protein that plays a central role in the development of 
extracellular senile plaques, through the generation of a peptide called amyloid-b (Ab) by 
proteolysis of the precursor protein (see [92, 93] and references therein).
Full-length APP contains three domains (Figure 1B): a large ECD that represents 
around 85% of the total protein mass (for the main neuronal isoform), a single-spanning 
TM domain, and a small cytoplasmic domain. The ECD consists of several subdomains 
with functional implications: a cysteine-rich region at the N-terminus with two subdomains, 
a growth factor-like domain (GFLD), which binds heparin (named also heparin-binding 
domain 1, HBD1), responsible for neurite outgrowth [94], and a copper-binding domain 
(CuBD) [95].  Cu2+ binding to CuBD reduces Ab production, probably through some 
alterations in signalling mechanisms and/or changes in the APP oligomerisation state [96].  
A 21-residues disulfide-bonded loop connects the GFLD with the CuBD domain and seems 
to be crucial for APP homodimerisation [97, 98]. The cysteine-rich region is followed by 
an acidic, random coil, Asp- and Glu-rich region (acidic domain or (DE)n domain), which 
contains two tyrosine-phosphorylation sites [99], a Kunitz-type protease inhibitor (KPI) 
domain and an OX2 domain.  The KPI and OX2 domains can be spliced out, to produce 
three main variants: APP770 (770 amino acid residues), APP751 and APP695, with the 
later being the principal neuronal isoform of human APP. The KPI domain can influence 
adhesion to extracellular matrix constituents, the activity of secreted APP-degrading 
proteases, and may act as a ligand for LPR1, a member of the LDL receptor gene family 
[100, 101].
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Following these domains there is a glycosylated domain (referred to as E2) and a 
largely unstructured juxtamembrane, random coil (RC) region that precedes the TM 
domain.  The E2 domain possesses a RERMS sequence that may be implicated in APP’s 
growth-promoting properties and binds heparin (named also heparin-binding domain 2, 
HBD2).  The a- and b–secretase cleavage sites are located within the RC region and it is 
possible that this sequence acquires secondary and/or tertiary structure in the presence of 
secretases as recently suggested [92]. The APP intracellular domain (AICD) is the centre of 
a complex network of protein-protein interactions whose relevance is highly controversial
[102, 103].
Two sites in the ECD seem to be critical for full-length APP homodimerisation [97, 
104], and a third site localized within the TM sequence of APP determines g–secretase 
cleavages [105]. The homophilic binding mechanism of APP is actually a subject of debate, 
with enormous interest due to putative implications in APP function and regulatory aspects 
for APP amyloidogenic processing.
                                                                                                                                                                                                                                                
APP transmembrane domain and membranotropic regions
The TM segment of APP is highly hydrophobic (Figure 1B) and computer algorithms 
predict an a–helix of 24 amino acids that can span the plasma membrane. Fifteen point 
mutations associated with familial Alzheimer disease (FAD) localize in the TM region at 
positions 705, 713, 714, 715, 716, 717 and 723 according to the Alzheimer Disease 
Mutation Database [106].
In the absence of full-length APP atomic structure, it has been recently reported the 
first structural study of the 99-residue C-terminal region (C99) of APP (residues D672-
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N770, Figure 1B) that includes the TM domain [107].  NMR data in 
lysomyristoylphosphatidylglycerol (LMPG) micelles reveals three a-helical segments 
(Figure 2B): i) a short surface-associated helix (F690-E693) preceding the TM segment at 
the extracellular side that may serve as an small anchor to organise the connecting loop to 
the TM domain, ii) a membrane-spanning region (G700-L723), which is essential for Ab
production, iii) an amphipathic membranotropic helix at the C-terminal end of the cytosolic 
domain (T761-N770) that plays critical roles in APP trafficking and protein-protein 
interactions. Three canonical GxxxG motifs are present (Figure 1B), one located in the 
juxtamembrane ECD (G696SNKG700), with two others in the TM region (G700AIIG704 and 
G704LMVG708). It should be noted that a GxxxG-like motif, G709VVIA713, (a glycine 
residue is substituted by alanine) is also present, where the g–secretase cleavage sites that 
generate Ab peptides are localized (see Figure 1B). As previously mentioned, GxxxG 
motifs are responsible for homodimerisation of GpA and many other membrane proteins 
[108], sometimes with repeats in tandem (Figure 3) [109]. Recent circular dichroism 
spectroscopy and fluorescence resonance energy transfer studies indicate that synthetic 
peptides corresponding to TM segments of APP adopted similar highly a–helical structures 
in sodium dodecyl sulphate (SDS) micelles and phosphatidylglycerol vesicles, and form 
stable dimers in both systems [110]. Interestingly, C99 was also observed to form dimers in 
LMPG micelles. In fact, the isolated TM peptides dimerise more avidly than full-length 
C99, indicating that the native extramembrane domains can influence dimer association 
[107].
In recent years, at least three models have been proposed for the APP TM dimeric 
structure, all involving GxxxG or GxxxG-like motifs.  In the first model based on site-
17
directed mutagenesis in a neuronal cell system, it was predicted that the interaction that 
stabilizes homodimer helix-helix contacts is primarily mediated by the GxxxG motif 
located at the beginning of the TM region [105], i.e. G700AIIG704 in the hAPP770 sequence. 
Mutations of glycine residues in this motif gradually attenuate the TM dimerisation 
strength. g-secretase cleavages of APP were shown to be intimately linked to the 
dimerisation strength of the TM substrate and a sequential mechanism for g-secretase 
cleavages on dimeric APP TMs (see below) has been postulated [105]. Using synthetic 
peptides corresponding to the APP TM segment (G700 to L723) and FAD mutant 
derivatives, a second model for TM dimer formation in SDS micelles has been proposed 
[110]. This model displays many similarities with the NMR structure of GpA TM helix 
dimer [111]. According to this second model, the putative dimerisation interface relies on 
the G709VVIA713 sequence (GpA uses G79VMAG83), with similar packing interfaces for
both sequences (APP 705-717 and GpA 75-87). It was hypothesized that FAD-APP 
mutations would destabilize the APP-TM dimer, increasing the population of APP peptide 
monomers.  Thus, it was argued that these mutations are ideally located to disrupt APP 
dimerisation [110]. In the third model [112], supported by recent solid-state NMR data 
[113], all three canonical GxxxG motifs (the juxtamembrane and the two located in the TM 
segment) have been proposed to simultaneously participate in the helix-helix interactions 
that are responsible for homodimerisation. In this model, the dimer interface is lined by 
glycines at positions 696, 700, 704, and 708 (hAPP770 numbering). It was demonstrated 
that pairwise replacement of glycines by leucines or isoleucines, but not alanines, in the 
central GxxxG motif results in a decrease in total Ab production (g-cleavage) without 
affecting the yield of AICD (e-cleavage, see below). In this respect, molecular dynamic 
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simulations predicted that all the Gly residues involved in the GxxxG motifs are located at
the interface of the wild type TM dimer, and that Gly to Leu or Ile mutations will cause a 
rotation and the placement of other small residues in the interface (i.e. Gly709 and Ala713),
which hinders Ab generation [112]. In the same direction, replica-exchanged molecular 
dynamics simulations have predicted that the changes induced by these mutations might be 
due to the adoption of a different dimer conformation with a shift of some residues relative 
to the bilayer normal producing a mismatch between the g-cleavage site and the active site 
of g-secretase, which would reduce Ab secretion [114].
APP processing and transmembrane cleavage
APP is subject to alternative pathways of proteolytic processing, leading either to 
production of the Ab peptides or to non-amyloidogenic fragments.  a– or  b-secretase 
(Figure 1B) cleavage release its large ECD from the cell surface, a process referred to as 
‘shedding’.  APP770 processing by a-secretase results in cleavage after K687 and release 
of an 83-residue C–terminal fragment, C83 [93].  C83 is a TM polypeptide that is further 
processed by g-secretase, and the resulting peptide products are not amyloidogenic. 
Alternatively b-secretase (b-site APP cleaving enzyme 1, BACE1) cleaves after M671 
leading to a 99-residue TM C-terminal domain, C99 [115, 116]. The preferential cell 
surface partitioning of APP to cholesterol-enriched lipid rafts (which can then be 
internalised to endosomes enriched with b-secretase activity) is believed to be a decisive 
determinant of the competition between b- and a-secretase for initial proteolysis of APP 
[107, 117, 118]. Subsequent cleavage of C99 by g-secretase at membrane-embedded sites 
leads to release of both the Ab peptides and the water-soluble AICD domain (V721-N770). 
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Ab peptides have heterogeneous C-termini due to a somewhat imprecise intramembrane 
cleavage, and these peptides displayed different propensity to aggregate and to form 
amyloid deposits in neural tissue [119].  Ab peptides have been the subject of extensive 
structural characterization in solution, bound to model membranes or as part of aggregates
(reviewed in [120, 121]). It has been proposed that the sequence represented by Ab may 
adopt an a-helical structure when present in the full-length APP [112]. After BACE 
cleavage of APP at the b–position, C99 will likely assume a dimer conformation with the 
GxxxG motifs in the interface (see above), and will be processed to form Ab peptides and 
AICD.  Once Ab is generated, the GxxxG motifs (in other words, the abundance of b-prone 
residues like glycine) would then promote a conformational change from a–helix to b–
strand with the formation of neurotoxic amyloid fibrils [122].
Similar to other intramembrane cleaving proteases, g-secretase cleaves C99-derived 
polypeptide at several locations (g-site, z-site and e–site, Figure 1B) probably through a 
sequential proteolytic pathway (processive model, reviewed in [115]). This proteolysis 
would start at the C-terminus of TM a-helix, near the membrane-cytosolic interface, 
sequentially yielding Ab49 precursor (e-cleavage), Ab46 (z-cleavage), and Ab42/40 (g-
cleavage), respectively. Inhibition of C99 dimerisation by mutating its first TM GxxxG 
motif has been shown to reduce the production of Ab42/40 forms with an increase of non-
pathogenic Ab38/35 shorter forms [105]. Thus, it has been also proposed that g-secretase 
removes consecutive fragments from the dimeric helical TM C-terminus, helix turn by 
helix turn, until cleavage reaches a certain distance from the G700AIIG704 dimerisation
motif, since this motif sterically hinders g-secretase proteolysis. Recent structural data 
support this progressive cleavage mechanism that requires the protease access to the protein 
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backbone depends on a secondary structure change (here a helix-to-coil transition) at the 
TM-justamembrane interface [113]. In this process, the final cleavages occur after residue 
V711 and/or A713 and produce mainly Ab40/42 peptides respectively (Figure 1B). 
Perturbed dimers (G700/G704 substituted to alanine) resolve the steric hindrance and allow 
the g-secretase to proceed, yielding Ab38/35 shorter peptides [105]. Membrane retention 
studies of Ab segments in microsomal membranes suggests that shorter segments (Ab 40-
45) are not integrated into the membrane, while longer ones (Ab 46-49) are efficiently 
retained in the lipid milieu [123]. Since dimer formation seems to be an important feature 
for g-secretase activity and this process is likely driven by helix-helix packing, modulating 
TM interactions arises as a new target for Alzheimer therapeutic intervention.
APP processing is affected by other factors. g-secretase and its substrates are 
compartmentalized into discrete membrane microdomains and emerging evidence suggest 
an intimate relationship between cholesterol-containing lipid rafts and APP processing 
[124, 125]. Recent NMR studies indicate that C99 specifically binds cholesterol, an agent 
that promotes the amyloidogenic pathway [118, 126], at the loop connecting the short 
membrane-associated helix to the TM domain [107]. Interestingly, this loop contains a 
VGSNK sequence immediately preceding the TM region (Figure 1B) that can be 
considered as a CRAC-like motif (canonical Tyr in the middle of the motif [37] is 
substituted by Ser, both Y/S side chains contain a hydroxyl group that can satisfy 
cholesterol interaction as proposed [36]). Cholesterol binding of this region would be based 
on H-bond interactions by wrapping and blocking the interfacial cholesterol OH-group. 
This interaction would give APP the capacity to bind cholesterol-rich domains in biological 
membranes. On the other hand, protein-protein interactions probably also contributes to 
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APP’s propensity to partition into cholesterol-rich domains. In this regard, it has been 
recently shown that flotillins facilitate clustering of both APP and cholesterol in raft-like 
membrane domains [127], and LDL receptor-related proteins (LRPs) have been also 
implicated in raft association, internalization and amyloidogenic processing of APP [101, 
107, 128]. Moreover, various cytosolic adaptor proteins have been reported to bind APP 
and influence its processing [103, 115], and novel insights for APP phosphorylation have 
been documented [129]. An interactome map has been derived that confirmed eight 
previously reported interactions of APP and revealed the identity of more than 30 
additional proteins that reside in spatial proximity to APP in the brain [130]. The putative 
role of these proteins in APP processing remains to be determined. Additionally, it has been 
reported that protein kinases that phosphorylate APP are able to phosphorylate the neuronal 
protein tau (present in the intraneuronal neurofibrillary tangles). It has been argued that this 
may be an important factor linking the two characteristic lesions of Alzheimer disease
[131].
Therapies in Alzheimer Disease
Therapeutic approaches for AD are guided by four disease characteristics: amyloid plaques, 
neurofibrillar tangles, neurodegeneration, and dementia (reviewed in [132, 133]). Current 
treatments for dementia symptoms are based on the ‘cholinergic deficit hypothesis’ and 
include FDA-approved, cognition-enhancer, acetylcholinesterase inhibitors (ChEIs) 
(reviewed in [134, 135]), and an NMDA (N-Methyl-D-Aspartate) receptor antagonist used 
as adjuvant to ChEI theraphy [135]. Since ChEIs have modest efficacy, recent drug 
developments point towards M1 muscarinic agonists [134] and multi-target-directed 
ligands as potential disease modifiers [136, 137].
22
However, the most used hypothesis explaining the pathophysiology of AD is the 
‘amyloid hypothesis’ centered in the premise that accumulation of Ab in the brain leads to 
oxidative stress, neuronal destruction and finally the clinical syndrome of AD [135]. 
According to this, a great number of anti-amyloid therapies are currently under 
investigation and clinical trials are in progress. Efforts are being directed to: i) decreasing 
Ab production, including inhibition of b- [138] and g-secretase, and modulators to produce 
shorter, non-toxic Ab fragments [139], as well as activation of a-secretase pathway [135]; 
ii) increasing Ab clearance including Ab immunotherapy [140], active (vaccination) and 
passive (monoclonal antibodies) immunization [141], and Ab degradation proteases [142]; 
iii) inhibition of Ab aggregation including peptides or peptidomimetics [143], b-sheet 
packing peptide inhibitors [122], polyphenols [144], intervention of Ab-metal (Zn/Cu) 
interactions [145] and glycosaminoglycan inhibitors [146].  At present, the g-secretase 
modulator Tarenflurbil or Flurizan [147] and a synthetic glycosaminoglycan (3APS, 
tramiprosate, Alzhemed) Ab-aggregation inhibitor [148], are being tested in phase III trials.
Concluding remarks
APP and gp41 TM proteins shared astounding structural characteristics and sequence 
motifs with functional significance, especially in their TM domains and membranotropic 
regions. The presence of GxxxG motifs that drives protein oligomerisation in membranes, 
and the similarity in the location of a specific cholesterol-binding site (CRAC motif) that 
can facilitate the clustering of the proteins in cholesterol-rich domains are clearly 
remarkable (Figure 2). b-amyloid in Alzheimer disease is related with APP association with 
cholesterol-enriched microdomains for conversion from non-pathogenic to pathogenic 
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forms. Accumulating evidence suggests that many viruses may hijack these dynamic lipid 
platforms to be used as an entry portal to the target cell. Even more, similarly to Ab
peptide, the gp41 FP region has been considered amyloidogenic (‘amyloid-like’ peptide) 
[32], and recent results have suggested that FP bound to membranes as b-sheets may 
contribute to the cytopathocity of HIV in vivo through an amyloid-type mechanism [33]. 
Finally, it is worth mentioning that, as previously stated, the gp41 TM domain is essential 
for HIV fusion activity and APP TM domain is critical for Ab production. To the extend 
that in both cases oligomerisation of the TM domains play a relevant role, it is tempting to 
speculate that agents that modulate helix-helix interactions may also be effective new 
therapies. In the last years efforts are being directed to design peptides and small molecules 
that can interact with TM helices in a sequence-specific manner [5, 6].  All in all, 
interfering TM interactions by searching for drugs that selectively modulate helix-helix 
packing may be a promising new target for HIV inhibitor development and to intervene 
with APP amyloidogenic processing.
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FIGURE LEGENDS
Figure 1. Schematic representation of HIV-1 gp41 (A) and APP (B). TM domain and 
membranotropic sequences in each protein are depicted darker. TM and juxtamembrane 
regions are enlarged and for APP the sequence involved in processing is shown with the 
major sites of cleavage by a-, b-, and g-secretases highlighted. Dashed arrows indicate APP 
intramembrane cleavage sites. The CRAC motifs are underlined. TM glycines and alanine 
residues involved in GxxxG/A motifs are shown in bold. Locations of gp41 inhibitor 
peptides and Ab 40/42 peptides are depicted with dark lines. Numbering refers to HIV 
gp160 precursor, BH10 isolate (A) and human APP770 isoform (B). See text for details.
Figure 2. Simplified membrane topology models for TM and membranotropic regions. (A) 
monomeric HIV-1 gp41. (B) monomeric APP. (C) TM segment oligomeric schemes: gp41 
trimer (left) and APP dimer (right). The predicted location of gp41 TM segment, a-helical 
MPER region and LLPs helices are shown. The two surface-membrane associated helices 
of APP are depicted according to [107].
Figure 3. Amino acid sequences of membrane spanning domains containing GxxxG and/or 
GxxxG-like motifs, for GpA and other membrane proteins from viral and neuronal origin. 
The amino acid residues of the putative TM domains are shown as upper case letters and 
flanking sequences are shown as lower case. Glycine and alanine residues in GxxxG/A 
motifs are in bold. HIV-1 consensus TM sequence (according to Shang et al. [59]); ScoV-
S: SARS coronavirus spike protein; APP and ErbB4 are g-secretase substrates; presenilin-1 
(PS-1) and anterior pharynx defective protein-1 (APH-1) are components of the g-secretase 
complex; p75: neurotrophin receptor protein [149]. For other abbreviations see text.
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